Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 69-76

  Conconi, Annarita ^a,b   Raderer, Markus ^c   Franceschetti, Silvia ^a   Devizzi, Liliana ^d   Ferreri, Andrés J M ^e   Magagnoli, Massimo ^f   Arcaini, Luca ^g,h   Zinzani, Pier Luigi ⁱ   Martinelli, Giovanni ^j   Vitolo, Umberto ^k   Kiesewetter, Barbara ^c   Porro, Elena ^l   Stathis, Anastasios ^l   Gaidano, Gianluca ^a   Cavalli, Franco ^l   Zucca, Emanuele ^l  

^a Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^b OSPEDALE DEGLI INFERMI   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k MOLINETTE HOSPITAL   (Italy)

^l OSPEDALE SAN GIOVANNI   (Switzerland)

more..

Author keywords

Everolimus; Mammalian target of rapamycin; Marginal zone B cell lymphoma; Mucosa associated lymphoid tissue lymphoma; Non Hodgkin lymphoma

Indexed keywords

EVEROLIMUS;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CAUSE OF DEATH; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; LUNG TOXICITY; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TOOTH INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; VERY ELDERLY;

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MARGINAL ZONE B-CELL LYMPHOMA; MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NON-HODGKIN LYMPHOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84902357461     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12845     Document Type: Article

References (33)

1. Altman, D.G., De Stavola, B.L., Love, S.B. & Stepniewska, K.A. (1995) Review of survival analyses published in cancer journals. British Journal of Cancer, 72, 511-518.
2. Brown, J.R., Friedberg, J.W., Feng, Y., Scofield, S., Phillips, K., Dal Cin, P., Joyce, R., Takvorian, R.W., Fisher, D.C., Fisher, R.I., Liesveld, J., Marquis, D., Neuberg, D. & Freedman, A.S. (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology, 145, 741-748.
3. Campo, E., Pileri, S.A., Jaffe, E.S., Muller-Hermelink, H.K. & Nathwani, B.N. (2008) Nodal marginal zone lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (eds by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 218-219. IARC, Lyon.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Conconi, A., Martinelli, G., Thieblemont, C., Ferreri, A.J., Devizzi, L., Peccatori, F., Ponzoni, M., Pedrinis, E., Dell'Oro, S., Pruneri, G., Filipazzi, V., Dietrich, P.Y., Gianni, A.M., Coiffier, B., Cavalli, F. & Zucca, E. (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 102, 2741-2745.
6. Conconi, A., Martinelli, G., Lopez-Guillermo, A., Zinzani, P.L., Ferreri, A.J., Rigacci, L., Devizzi, L., Vitolo, U., Luminari, S., Cavalli, F. & Zucca, E.; International Extranodal Lymphoma Study Group (IELSG) (2011) Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Annals of Oncology, 22, 689-695.
7. Copie-Bergman, C., Wotherspoon, A.C., Capella, C., Motta, T., Pedrinis, E., Pileri, S.A., Bertoni, F., Conconi, A., Zucca, E., Ponzoni, M. & Ferreri, A.J. (2013) Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. British Journal of Haematology, 160, 47-52.
8. Di Bella, N., Taetle, R., Kolibaba, K., Boyd, T., Raju, R., Barrera, D., Cochran, E.W. Jr, Dien, P.Y., Lyons, R., Schlegel, P.J., Vukelja, S.J., Boston, J., Boehm, K.A., Wang, Y. & Asmar, L. (2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 115, 475-480.
9. Ghobrial, I.M., Gertz, M., Laplant, B., Camoriano, J., Hayman, S., Lacy, M., Chuma, S., Harris, B., Leduc, R., Rourke, M., Ansell, S.M., Deangelo, D., Dispenzieri, A., Bergsagel, L., Reeder, C., Anderson, K.C., Richardson, P.G., Treon, S.P. & Witzig, T.E. (2010) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology, 28, 1408-1414.
10. Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L. & Coiffier, B. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27, 3822-3829.
11. Isaacson, P.G., Chott, A., Nakamura, S., Muller-Hermelink, H.K., Harris, N.H. & Swerdlow, S.H. (2008a) Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (eds by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 214-217. IARC, Lyon.
12. Isaacson, P.G., Piris, M.A., Berger, F., Swerdlow, S.H., Thieblemont, C., Pittaluga, S. & Harris, N.L. (2008b) Splenic B-cell marginal zone lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (eds by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 185-187. IARC, Lyon.
13. Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., Reeder, C.B., Roy, V. & Witzig, T.E. (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology, 85, 320-324.
14. Kalbfleisch, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York.
15. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
16. Kiesewetter, B., Troch, M., Dolak, W., Müllauer, L., Lukas, J., Zielinski, C.C. & Raderer, M. (2013) A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associatedlymphoid tissue (MALT lymphoma). Haematologica, 98, 353-356.
17. Loomba, R., Rowley, A., Wesley, R., Liang, T.J., Hoofnagle, J.H., Pucino, F. & Csako, G. (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine, 148, 519-528.
18. Montalbán, C., Abraira, V., Arcaini, L., Domingo-Domenech, E., Guisado-Vasco, P., Iannitto, E., Mollejo, M., Matutes, E., Ferreri, A., Salar, A., Rattotti, S., Carpaneto, A., Pérez Fernández, R., Bello, J.L., Hernández, M., Caballero, D., Carbonell, F. & Piris, M.A.; Splenic Marginal Zone Lymphoma Study Group (2012) Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. British Journal of Haematology, 159, 164-171.
19. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
20. Oki, Y., Buglio, D., Fanale, M., Fayad, L., Copeland, A., Romaguera, J., Kwak, L.W., Pro, B., de Castro Faria, S., Neelapu, S., Fowler, N., Hagemeister, F., Zhang, J., Zhou, S., Feng, L. & Younes, A. (2013) Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clinical Cancer Research, 19, 6882-6890.
21. Renner, C., Zinzani, P.L., Gressin, R., Klingbiel, D., Dietrich, P.Y., Hitz, F., Bargetzi, M., Mingrone, W., Martinelli, G., Trojan, A., Bouabdallah, K., Lohri, A., Gyan, E., Biaggi, C., Cogliatti, S., Bertoni, F., Ghielmini, M., Brauchli, P. & Ketterer, N.; Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network (2012) A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97, 1085-1091.
22. Rinaldi, A., Mian, M., Chigrinova, E., Arcaini, L., Bhagat, G., Novak, U., Rancoita, P.M., De Campos, C.P., Forconi, F., Gascoyne, R.D., Facchetti, F., Ponzoni, M., Govi, S., Ferreri, A.J., Mollejo, M., Piris, M.A., Baldini, L., Soulier, J., Thieblemont, C., Canzonieri, V., Gattei, V., Marasca, R., Franceschetti, S., Gaidano, G., Tucci, A., Uccella, S., Tibiletti, M.G., Dirnhofer, S., Tripodo, C., Doglioni, C., Dalla Favera, R., Cavalli, F., Zucca, E., Kwee, I. & Bertoni, F. (2011) Genome-wide DNA profiling of marginl zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 117, 1595-1604.
23. Schatz, J.H. (2011) Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Current Oncology Reports, 13, 398-406.
24. Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1-10.
25. Smith, S.M., van Besien, K., Karrison, T., Dancey, J., McLaughlin, P., Younes, A., Smith, S., Stiff, P., Lester, E., Modi, S., Doyle, L.A., Vokes, E.E. & Pro, B. (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. Journal of Clinical Oncology, 28, 4740-4746.
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
27. Troch, M., Kiesewetter, B., Willenbacher, W., Willenbacher, E., Zebisch, A., Linkesch, W., Fridrik, M., Müllauer, L., Greil, R. & Raderer, M. (2013) Rituximab plus subcutaneous cladribine in patients ith extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica, 98, 264-268.
28. Witzig, T.E., Reeder, C.B., LaPlant, B.R., Gupta, M., Johnston, P.B., Micallef, I.N., Porrata, L.F., Ansell, S.M., Colgan, J.P., Jacobsen, E.D., Ghobrial, I.M. & Habermann, T.M. (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341-347.
29. Zent, C.S., LaPlant, B.R., Johnston, P.B., Call, T.G., Habermann, T.M., Micallef, I.N. & Witzig, T.E. (2010) The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer, 116, 2201-2207.
30. Zinzani, P.L., Stefoni, V., Musuraca, G., Tani, M., Alinari, L., Gabriele, A., Marchi, E., Pileri, S. & Baccarani, M. (2004) Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer, 100, 2190-2194.
31. Zucca, E., Conconi, A., Pedrinis, E., Cortelazzo, S., Motta, T., Gospodarowicz, M.K., Patterson, B.J., Ferreri, A.J., Ponzoni, M., Devizzi, L., Giardini, R., Pinotti, G., Capella, C., Zinzani, P.L., Pileri, S., López-Guillermo, A., Campo, E., Ambrosetti, A., Baldini, L. & Cavalli, F.; International Extranodal Lymphoma Study Group (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood, 101, 2489-2495.
32. Zucca, E., Bertoni, F., Stathis, A. & Cavalli, F. (2008) Marginal zone lymphomas. Hematology/Oncology Clinics of North America, 22, 883-901.
33. Zucca, E., Conconi, A., Laszlo, D., López-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., Vitolo, U., Morschhauser, F., Pileri, S.A., Copie-Bergman, C., Campo, E., Jack, A., Floriani, I., Johnson, P., Martelli, M., Cavalli, F., Martinelli, G. & Thieblemont, C. (2012) Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. Journal of Clinical Oncology, 31, 565-572.